Sugi Predict

Sugi Predict / Compounds / SCHEMBL733741

SCHEMBL733741

SCHEMBL733741

CC(C)(C)OC(=O)N1CCC2(CC2)C(O)C1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NR1H2 P55055 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ GPR119 Q8TDV5 2/20 0.40
▸ NAMPT P43490 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ CHRM2 P08172 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ KDM1A O60341 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9942499 1.00 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL734925 1.00 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL24938934 0.94 HPGD (0.42) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL30744670 0.94 HPGD (0.42) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL18204175 0.90 NR1H2 (0.40) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL17499918 0.85 NR1H2 (0.43) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL2904469 0.85 USP2 (0.45) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL30186133 0.85 USP2 (0.45) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL5766899 0.84 USP2 (0.47) USP2SMN1; SMN2NR1H2HPGDMEN1
SCHEMBL5764149 0.84 USP2 (0.47) USP2SMN1; SMN2NR1H2HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122171-A1 Substituted Amine Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. 2025-04-17 — — US disclosed
WO-2025081019-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2025-04-17 — — WO disclosed
WO-2025064534-A1 SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2025-03-27 — — WO disclosed
WO-2024083208-A1 KIF18A PROTEIN INHIBITOR 杭州邦顺制药有限公司 2024-04-25 — — WO disclosed
CN-117917405-A KIF18A protein inhibitors 杭州邦顺制药有限公司 2024-04-23 — — CN disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 — — US disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 — — US disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 — — US disclosed
EP-2491022-B1 DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2014-12-31 — — EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 — — US disclosed
WO-2011048032-A1 DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-28 — — WO disclosed
US-20110092698-A1 NOVEL HETEROCYCLYL COMPOUNDS F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2011-04-21 — — US disclosed
EP-2307387-A1 NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE F. Hoffmann-La Roche AG (CH) 2011-04-13 — — EP disclosed
EP-2220055-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2010-08-25 — — EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 — — WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 — — US disclosed
WO-2010006938-A1 NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2010-01-21 — — WO disclosed
US-20100016282-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-21 — — US disclosed
US-20090023713-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE, INC. 2009-01-22 — — US disclosed
WO-2009010429-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122171-A1 Substituted Amine Compounds, Compositions and Methods of Use MRGPRX2, MRGPRX1, MRGPRX4 USP2 4037/4885SMN1; SMN2 1078/4885NR1H2 353/4885
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 USP2 4741/4885SMN1; SMN2 4455/4885NR1H2 181/4885
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 USP2 3563/4885SMN1; SMN2 4085/4885NR1H2 4174/4885
US-20090023713-A1 HETEROCYCLIC COMPOUNDS CCR5, CCR3, CCR2 USP2 4800/4885SMN1; SMN2 4301/4885NR1H2 135/4885
US-20100016282-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 USP2 4729/4885SMN1; SMN2 4376/4885NR1H2 222/4885
US-20110092698-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR1 USP2 4760/4885SMN1; SMN2 3766/4885NR1H2 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.